Bio-Path Holdings Inc (NASDAQ:BPTH)
North American company
Share Price Chart
- Chart currently unavailable -
Market Info - BPTH
- Market Open Price0.00
- Previous Close0.00
- Volume-
- 52w Low/High-
- Last Trade Price0.00
- Bid/Ask Price0.00
Company Info - BPTH
- Market Cap$19.390m
- SymbolNASDAQ:BPTH
- IndustryHealthcare
- SectorBiotechnology
- Currency
- ISINUS09057N3008
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.Bio-Path Holdings Inc is a clinical and preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.
Latest BPTH news
Currently there for this company. Visit our news hub for other news .